CooperVision Canada Marks Fifth Year of Raising Awareness About Childhood Myopia and Treatment Options
MiSight® 1 day contact lenses from CooperVision can help age-appropriate children with myopia reach their full potential. MiSight® 1 day is the first and only FDA approved* soft contact lens proven to slow the progression of myopia in children aged 8-12 at the initiation of treatment.1†
Myopia, or nearsightedness, is a common condition where distant objects appear blurry while close-up vision remains clear. It often develops during childhood, typically beginning in the early school years.2-3 A 2018 study from the
MiSight® 1 day contact lenses are designed to be part of a proactive myopia management treatment plan,1† providing freedom from glasses and slowing the worsening of myopia1† during a child's most critical years of growth.
"When children develop myopia at a younger age, their condition tends to worsen more rapidly into their late teens,7 which increases their risk of sight-threatening eye health conditions later in life,8" said
August is
MiSight® 1 day is also uniquely backed by a multi-year, peer-reviewed clinical study that demonstrated sustained slowing of myopia progression in children who wore the lenses daily, compared to those wearing single-vision lenses.1,10-13 The results showed not only significant slowing of eye length growth1† but also excellent vision correction1,10± and high satisfaction among young wearers and their parents.14≠
Over a 3-year period, MiSight® 1 day contact lenses slowed myopia progression by 59% on average.1† Parent-approved MiSight® 1 day contact lenses saw 90% of parents whose children wore the lenses report that their children were extremely happy14≠ wearing MiSight® 1 day lenses and strongly preferred them over their glasses.15
MiSight® 1 day contact lenses are available through licensed Canadian eye care professionals.
To learn more about myopia and MiSight® 1 day, visit fightmyopia.ca.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges, such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas, and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.ca.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in
Indications and Important Safety Information. Rx only. Results may vary. |
|
ATTENTION: Reference the Patient Information Booklet for a complete listing of Indications and Important Safety Information. This product may not be right for you, talk to your Eye Care Professional. |
|
* |
|
†Compared to single-vision lenses over a three-year period. |
|
References: |
|
1. |
Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567. |
2. |
Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042.] |
3. |
Hou W, Norton TT, Hyman L, Gwiazda J; |
4. |
Yang M, Luensmann D, Fonn D, Woods J, Jones D, Gordon K, Jones L. Myopia prevalence in Canadian school children: a pilot study. Eye (Lond). 2018 Jun;32(6):1042-1047. |
5. |
Lanca C, Saw SM. The association between digital screen time and myopia: A systematic review. Ophthalmic Physiol Opt. 2020 Mar;40(2):216-229. |
6. |
Jonas JB, et al., IMI Prevention of Myopia and Its Progression. Invest Ophthalmol Vis Sci. 2021 Apr 28;62(5):6. |
7. |
|
8. |
Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog |
9. |
Woods J, et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391. |
10. |
Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci. 2022 |
11. |
Chamberlain, Arumugam, et al. Myopia progression cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci. 2021;98:E-abstract 210049. |
12. |
Woods J, et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391. |
13. |
Sulley A, et al. Experience and subjective responses for children switched from single vision to dual focus myopia control daily disposable contact lenses. BCLA paper presentation 2021. |
14. |
CVI data on file 2018. 3-year data for RCT with MiSight® 1 day and Proclear 1 day. |
15. |
Sulley A et al. Wearer experience and subjective responses with dual focus compared to spherical, single vision soft contact lenses in children during a 3-year clinical trial. AAO 2019 Poster. |
SOURCE CooperVision